Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/110372
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCurrow, D.en
dc.contributor.authorWatts, G.en
dc.contributor.authorJohnson, M.en
dc.contributor.authorMcDonald, C.en
dc.contributor.authorMiners, J.en
dc.contributor.authorSomogyi, A.en
dc.contributor.authorDenehy, L.en
dc.contributor.authorMcCaffrey, N.en
dc.contributor.authorEckert, D.en
dc.contributor.authorMcCloud, P.en
dc.contributor.authorLouw, S.en
dc.contributor.authorLam, L.en
dc.contributor.authorGreene, A.en
dc.contributor.authorFazekas, B.en
dc.contributor.authorClark, K.en
dc.contributor.authorFong, K.en
dc.contributor.authorAgar, M.en
dc.contributor.authorJoshi, R.en
dc.contributor.authorKilbreath, S.en
dc.contributor.authorFerreira, D.en
dc.contributor.authoret al.en
dc.date.issued2017en
dc.identifier.citationBMJ Open, 2017; 7(7):e018100-1-e018100-18en
dc.identifier.issn2044-6055en
dc.identifier.issn2044-6055en
dc.identifier.urihttp://hdl.handle.net/2440/110372-
dc.description.abstractIntroduction: Chronic breathlessness is highly prevalent and distressing to patients and families. No medication is registered for its symptomatic reduction. The strongest evidence is for regular, low-dose, extended- release (ER) oral morphine. A recent large phase III study suggests the subgroup most likely to benefit have chronic obstructive pulmonary disease (COPD) and modified Medical Research Council breathlessness scores of 3 or 4. This protocol is for an adequately powered, parallel-arm, placebo-controlled, multisite, factorial, block-randomised study evaluating regular ER morphine for chronic breathlessness in people with COPD. Methods and analysis: The primary question is what effect regular ER morphine has on worst breathlessness, measured daily on a 0-10 numerical rating scale. Uniquely, the coprimary outcome will use a FitBit to measure habitual physical activity. Secondary questions include safety and, whether upward titration after initial benefit delivers greater net symptom reduction. Substudies include longitudinal driving simulation, sleep, caregiver, health economic and pharmacogenetic studies. Seventeen centres will recruit 171 participants from respiratory and palliative care. The study has five phases including three randomisation phases to increasing doses of ER morphine. All participants will receive placebo or active laxatives as appropriate. Appropriate statistical analysis of primary and secondary outcomes will be used. Ethics and dissemination: Ethics approval has been obtained. Results of the study will be submitted for publication in peer-reviewed journals, findings presented at relevant conferences and potentially used to inform registration of ER morphine for chronic breathlessness. Trial registration number: NCT02720822; Pre-results.en
dc.description.statementofresponsibilityDavid Currow, Gareth John Watts, Miriam Johnson, Christine F McDonald, John O Miners, Andrew A Somogyi, Linda Denehy, Nicola McCaffrey, Danny J Eckert, Philip McCloud, Sandra Louw, Lawrence Lam, Aine Greene, Belinda Fazekas, Katherine C Clark, Kwun Fong, Meera R Agar, Rohit Joshi, Sharon Kilbreath, Diana Ferreira, Magnus Ekström, on behalf of the Australian national Palliative Care Clinical Studies Collaborative (PaCCSC)en
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.rights© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectAustralian national Palliative Care Clinical Studies Collaborative (PaCCSC)en
dc.titleA pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion and Morphine Sulfate (BEAMS) study protocolen
dc.typeJournal articleen
dc.identifier.rmid0030073316en
dc.identifier.doi10.1136/bmjopen-2017-018100en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1065571en
dc.identifier.pubid365100-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
dc.identifier.orcidMcCaffrey, N. [0000-0003-3684-3723]en
dc.identifier.orcidJoshi, R. [0000-0003-4607-3937]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_110372.pdfPublished Version641.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.